256 related articles for article (PubMed ID: 17544551)
1. Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules does not enhance effector or memory CTL responses afforded by immunisation with a tumour antigen-encoding DNA vaccine.
Herd KA; Wiethe C; Tindle RW
Vaccine; 2007 Jul; 25(28):5209-19. PubMed ID: 17544551
[TBL] [Abstract][Full Text] [Related]
2. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
3. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination.
Du X; Zheng G; Jin H; Kang Y; Wang J; Xiao C; Zhang S; Zhao L; Chen A; Wang B
J Gene Med; 2007 Feb; 9(2):136-46. PubMed ID: 17310492
[TBL] [Abstract][Full Text] [Related]
4. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.
Grünebach F; Kayser K; Weck MM; Müller MR; Appel S; Brossart P
Cancer Gene Ther; 2005 Sep; 12(9):749-56. PubMed ID: 15877082
[TBL] [Abstract][Full Text] [Related]
5. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
Kuang Y; Weng X; Liu X; Zhu H; Chen Z; Jiang B; Chen H
Cancer Lett; 2010 Jul; 293(2):254-62. PubMed ID: 20149524
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
U'Ren L; Kedl R; Dow S
Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
[TBL] [Abstract][Full Text] [Related]
9. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
10. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines.
Iwasaki A; Stiernholm BJ; Chan AK; Berinstein NL; Barber BH
J Immunol; 1997 May; 158(10):4591-601. PubMed ID: 9144471
[TBL] [Abstract][Full Text] [Related]
11. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
12. Costimulation provided by DNA immunization enhances antitumor immunity.
Corr M; Tighe H; Lee D; Dudler J; Trieu M; Brinson DC; Carson DA
J Immunol; 1997 Nov; 159(10):4999-5004. PubMed ID: 9366427
[TBL] [Abstract][Full Text] [Related]
13. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine.
Xu W; Chu Y; Zhang R; Xu H; Wang Y; Xiong S
Virology; 2005 Apr; 334(2):255-63. PubMed ID: 15780875
[TBL] [Abstract][Full Text] [Related]
14. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
15. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
[TBL] [Abstract][Full Text] [Related]
16. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
17. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
Fong CL; Mok CL; Hui KM
Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
[TBL] [Abstract][Full Text] [Related]
18. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
19. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand.
Gramaglia I; Cooper D; Miner KT; Kwon BS; Croft M
Eur J Immunol; 2000 Feb; 30(2):392-402. PubMed ID: 10671194
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
